Transforming the Lives of Patients with Diabetes

ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte's innovative product is based on the differentiation of stem cells into pancreatic beta cell precursors (PEC-01™), with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device (Encaptra® drug delivery system). Once implanted, the precursor cells mature into endocrine cells that secrete insulin and other hormones in a regulated manner to control blood glucose levels. ViaCyte's goal is a product that can free patients with type 1 and type 2 diabetes from long-term insulin dependence. ViaCyte has received substantial financial support from both the California Institute for Regenerative Medicine (CIRM) and JDRF.

Stem Cell-Derived Islet Replacement Therapies

ViaCyte is developing islet cell replacement therapy for insulin-requiring diabetes. Our two key products in development deploy the same active component, PEC-01 Cells, but with different delivery technologies and addressing the unmet needs of different patient groups.
Learn more about our product pipeline »

Hope for Patients with Diabetes

The Human Trial is an independent, feature-length documentary that is in the works, currently following ViaCyte’s quest to develop what might become a functional cure for type 1 diabetes (T1D).

Watch More Videos

Recent News

Our Partners